Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.35
AZN's Cash to Debt is ranked lower than
79% of the 697 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. AZN: 0.35 )
Ranked among companies with meaningful Cash to Debt only.
AZN' s 10-Year Cash to Debt Range
Min: 0.2  Med: 3.12 Max: N/A
Current: 0.35
Equity to Asset 0.32
AZN's Equity to Asset is ranked lower than
86% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. AZN: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
AZN' s 10-Year Equity to Asset Range
Min: 0.3  Med: 0.46 Max: 0.59
Current: 0.32
0.3
0.59
Interest Coverage 5.58
AZN's Interest Coverage is ranked lower than
86% of the 372 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 933.44 vs. AZN: 5.58 )
Ranked among companies with meaningful Interest Coverage only.
AZN' s 10-Year Interest Coverage Range
Min: 5.58  Med: 13.03 Max: 100.5
Current: 5.58
5.58
100.5
F-Score: 3
Z-Score: 2.09
M-Score: -3.03
WACC vs ROIC
8.08%
8.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 8.68
AZN's Operating margin (%) is ranked higher than
52% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.76 vs. AZN: 8.68 )
Ranked among companies with meaningful Operating margin (%) only.
AZN' s 10-Year Operating margin (%) Range
Min: 8.19  Med: 23.23 Max: 38.09
Current: 8.68
8.19
38.09
Net-margin (%) 4.97
AZN's Net-margin (%) is ranked lower than
54% of the 657 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.85 vs. AZN: 4.97 )
Ranked among companies with meaningful Net-margin (%) only.
AZN' s 10-Year Net-margin (%) Range
Min: 4.73  Med: 17.55 Max: 29.72
Current: 4.97
4.73
29.72
ROE (%) 6.36
AZN's ROE (%) is ranked higher than
51% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.03 vs. AZN: 6.36 )
Ranked among companies with meaningful ROE (%) only.
AZN' s 10-Year ROE (%) Range
Min: 5.75  Med: 33.61 Max: 42.98
Current: 6.36
5.75
42.98
ROA (%) 2.23
AZN's ROA (%) is ranked lower than
55% of the 702 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. AZN: 2.23 )
Ranked among companies with meaningful ROA (%) only.
AZN' s 10-Year ROA (%) Range
Min: 2.15  Med: 14.31 Max: 22.07
Current: 2.23
2.15
22.07
ROC (Joel Greenblatt) (%) 28.38
AZN's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.97 vs. AZN: 28.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AZN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 27.54  Med: 70.82 Max: 199.48
Current: 28.38
27.54
199.48
Revenue Growth (3Y)(%) -5.60
AZN's Revenue Growth (3Y)(%) is ranked lower than
81% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. AZN: -5.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AZN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -53.3  Med: 6.50 Max: 15.5
Current: -5.6
-53.3
15.5
EBITDA Growth (3Y)(%) -30.60
AZN's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 482 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.40 vs. AZN: -30.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AZN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -41.4  Med: 10.20 Max: 26.1
Current: -30.6
-41.4
26.1
EPS Growth (3Y)(%) -48.80
AZN's EPS Growth (3Y)(%) is ranked lower than
94% of the 450 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. AZN: -48.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AZN' s 10-Year EPS Growth (3Y)(%) Range
Min: -48.8  Med: 10.50 Max: 31.5
Current: -48.8
-48.8
31.5
» AZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AZN Guru Trades in Q2 2014

Jeremy Grantham 28,000 sh (New)
Paul Tudor Jones 27,100 sh (New)
Louis Moore Bacon 40,000 sh (New)
Mario Gabelli 40,400 sh (New)
George Soros 150,000 sh (New)
Jim Simons 1,794,800 sh (+25.60%)
Daniel Loeb 1,000,000 sh (unchged)
Steven Cohen 225,000 sh (unchged)
Steven Cohen 370,800 sh (unchged)
Francis Chou 13,000 sh (unchged)
Joel Greenblatt Sold Out
Murray Stahl 13,000 sh (-0.81%)
John Hussman 223,500 sh (-1.97%)
David Dreman 117,832 sh (-13.00%)
NWQ Managers 64,475 sh (-24.55%)
Manning & Napier Advisors, Inc 309,030 sh (-32.76%)
Stanley Druckenmiller 208,900 sh (-42.05%)
Pioneer Investments 225,804 sh (-50.84%)
Charles Brandes 386,058 sh (-71.06%)
» More
Q3 2014

AZN Guru Trades in Q3 2014

Steven Cohen 611,100 sh (+64.81%)
Mario Gabelli 41,900 sh (+3.71%)
Jim Simons 1,847,100 sh (+2.91%)
Manning & Napier Advisors, Inc 317,180 sh (+2.64%)
Murray Stahl 13,000 sh (unchged)
NWQ Managers 64,475 sh (unchged)
Francis Chou 13,000 sh (unchged)
Steven Cohen 400,000 sh (unchged)
George Soros 150,000 sh (unchged)
Pioneer Investments 227,221 sh (unchged)
Charles Brandes Sold Out
Jeremy Grantham Sold Out
Paul Tudor Jones Sold Out
Stanley Druckenmiller Sold Out
David Dreman 117,003 sh (-0.70%)
John Hussman 173,500 sh (-22.37%)
Louis Moore Bacon 30,000 sh (-25.00%)
» More
Q4 2014

AZN Guru Trades in Q4 2014

Pioneer Investments 754,327 sh (+231.98%)
Jim Simons 2,287,900 sh (+23.86%)
NWQ Managers 66,440 sh (+3.05%)
Francis Chou 13,000 sh (unchged)
Murray Stahl 13,000 sh (unchged)
John Hussman 173,500 sh (unchged)
George Soros Sold Out
Louis Moore Bacon Sold Out
Steven Cohen 587,400 sh (-3.88%)
Manning & Napier Advisors, Inc 227,870 sh (-28.16%)
Mario Gabelli 19,900 sh (-52.51%)
David Dreman 28,764 sh (-75.42%)
» More
Q1 2015

AZN Guru Trades in Q1 2015

Jim Simons 3,154,400 sh (+37.87%)
Pioneer Investments 758,498 sh (+0.55%)
Murray Stahl 13,000 sh (unchged)
Francis Chou 13,000 sh (unchged)
Manning & Napier Advisors, Inc 227,870 sh (unchged)
David Dreman 27,489 sh (-4.43%)
NWQ Managers 52,265 sh (-21.34%)
Mario Gabelli 11,800 sh (-40.70%)
John Hussman 52,000 sh (-70.03%)
Steven Cohen 61,800 sh (-89.48%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 64.10
AZN's P/E(ttm) is ranked lower than
76% of the 470 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.70 vs. AZN: 64.10 )
Ranked among companies with meaningful P/E(ttm) only.
AZN' s 10-Year P/E(ttm) Range
Min: 5.85  Med: 12.19 Max: 92.04
Current: 64.1
5.85
92.04
Forward P/E 15.60
AZN's Forward P/E is ranked higher than
72% of the 232 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.98 vs. AZN: 15.60 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 64.50
AZN's PE(NRI) is ranked lower than
77% of the 471 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.70 vs. AZN: 64.50 )
Ranked among companies with meaningful PE(NRI) only.
AZN' s 10-Year PE(NRI) Range
Min: 5.83  Med: 12.17 Max: 92.27
Current: 64.5
5.83
92.27
P/B 4.86
AZN's P/B is ranked lower than
63% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.39 vs. AZN: 4.86 )
Ranked among companies with meaningful P/B only.
AZN' s 10-Year P/B Range
Min: 2.29  Med: 3.77 Max: 7
Current: 4.86
2.29
7
P/S 3.20
AZN's P/S is ranked higher than
50% of the 647 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.27 vs. AZN: 3.20 )
Ranked among companies with meaningful P/S only.
AZN' s 10-Year P/S Range
Min: 1.41  Med: 2.34 Max: 4.09
Current: 3.2
1.41
4.09
PFCF 30.57
AZN's PFCF is ranked higher than
63% of the 276 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.86 vs. AZN: 30.57 )
Ranked among companies with meaningful PFCF only.
AZN' s 10-Year PFCF Range
Min: 6.15  Med: 13.24 Max: 34.13
Current: 30.57
6.15
34.13
POCF 14.22
AZN's POCF is ranked higher than
78% of the 385 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.88 vs. AZN: 14.22 )
Ranked among companies with meaningful POCF only.
AZN' s 10-Year POCF Range
Min: 5.19  Med: 8.48 Max: 19.86
Current: 14.22
5.19
19.86
EV-to-EBIT 52.00
AZN's EV-to-EBIT is ranked lower than
75% of the 482 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.80 vs. AZN: 52.00 )
Ranked among companies with meaningful EV-to-EBIT only.
AZN' s 10-Year EV-to-EBIT Range
Min: 4.3  Med: 9.20 Max: 52
Current: 52
4.3
52
Shiller P/E 14.86
AZN's Shiller P/E is ranked higher than
87% of the 311 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 38.44 vs. AZN: 14.86 )
Ranked among companies with meaningful Shiller P/E only.
AZN' s 10-Year Shiller P/E Range
Min: 7.48  Med: 12.93 Max: 29.06
Current: 14.86
7.48
29.06
Current Ratio 0.81
AZN's Current Ratio is ranked lower than
94% of the 605 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. AZN: 0.81 )
Ranked among companies with meaningful Current Ratio only.
AZN' s 10-Year Current Ratio Range
Min: 0.64  Med: 1.50 Max: 2.03
Current: 0.81
0.64
2.03
Quick Ratio 0.68
AZN's Quick Ratio is ranked lower than
89% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. AZN: 0.68 )
Ranked among companies with meaningful Quick Ratio only.
AZN' s 10-Year Quick Ratio Range
Min: 0.54  Med: 1.29 Max: 2.03
Current: 0.68
0.54
2.03
Days Inventory 132.85
AZN's Days Inventory is ranked lower than
61% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.04 vs. AZN: 132.85 )
Ranked among companies with meaningful Days Inventory only.
AZN' s 10-Year Days Inventory Range
Min: 98.03  Med: 146.29 Max: 290.36
Current: 132.85
98.03
290.36
Days Sales Outstanding 99.29
AZN's Days Sales Outstanding is ranked lower than
73% of the 592 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.21 vs. AZN: 99.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
AZN' s 10-Year Days Sales Outstanding Range
Min: 52.89  Med: 76.30 Max: 127.8
Current: 99.29
52.89
127.8

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.29
AZN's Dividend Yield is ranked higher than
97% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.19 vs. AZN: 4.29 )
Ranked among companies with meaningful Dividend Yield only.
AZN' s 10-Year Dividend Yield Range
Min: 1.77  Med: 4.44 Max: 6.99
Current: 4.29
1.77
6.99
Dividend Payout 2.77
AZN's Dividend Payout is ranked lower than
80% of the 394 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. AZN: 2.77 )
Ranked among companies with meaningful Dividend Payout only.
AZN' s 10-Year Dividend Payout Range
Min: 0.3  Med: 0.94 Max: 4.75
Current: 2.77
0.3
4.75
Dividend growth (3y) 1.20
AZN's Dividend growth (3y) is ranked lower than
65% of the 253 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. AZN: 1.20 )
Ranked among companies with meaningful Dividend growth (3y) only.
AZN' s 10-Year Dividend growth (3y) Range
Min: -4.7  Med: 10.90 Max: 28
Current: 1.2
-4.7
28
Yield on cost (5-Year) 5.82
AZN's Yield on cost (5-Year) is ranked higher than
95% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.55 vs. AZN: 5.82 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
AZN' s 10-Year Yield on cost (5-Year) Range
Min: 2.39  Med: 6.01 Max: 10.38
Current: 5.82
2.39
10.38
Share Buyback Rate 2.60
AZN's Share Buyback Rate is ranked higher than
93% of the 431 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.30 vs. AZN: 2.60 )
Ranked among companies with meaningful Share Buyback Rate only.
AZN' s 10-Year Share Buyback Rate Range
Min: 4.6  Med: 2.00 Max: -144.8
Current: 2.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.22
AZN's Price/Projected FCF is ranked higher than
85% of the 319 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.94 vs. AZN: 1.22 )
Ranked among companies with meaningful Price/Projected FCF only.
AZN' s 10-Year Price/Projected FCF Range
Min: 0.56  Med: 1.20 Max: 5.85
Current: 1.22
0.56
5.85
Price/Median PS Value 1.37
AZN's Price/Median PS Value is ranked lower than
55% of the 598 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.30 vs. AZN: 1.37 )
Ranked among companies with meaningful Price/Median PS Value only.
AZN' s 10-Year Price/Median PS Value Range
Min: 0.35  Med: 1.24 Max: 2.51
Current: 1.37
0.35
2.51
Earnings Yield (Greenblatt) (%) 1.90
AZN's Earnings Yield (Greenblatt) (%) is ranked lower than
52% of the 683 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. AZN: 1.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AZN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.9  Med: 10.90 Max: 23.4
Current: 1.9
1.9
23.4
Forward Rate of Return (Yacktman) (%) -12.35
AZN's Forward Rate of Return (Yacktman) (%) is ranked lower than
84% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.89 vs. AZN: -12.35 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AZN' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -15.7  Med: 18.90 Max: 27.6
Current: -12.35
-15.7
27.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:AZN.Sweden, AZN.UK, ZEG.Germany, AZN.Argentina, AZNN.Mexico, AZN.Switzerland, AZNCF.USA, ZEGA.Germany, AZNDF.USA,
AstraZeneca PLC was incorporated in England and Wales on June 17, 1992. From February 1993 until April 1999, the Company was called Zeneca Group PLC. On 6 April 1999, the Company changed its name to AstraZeneca PLC. It is a biopharmaceutical company. The Company is engaged in the discovery and development of new products, which are then manufactured, marketed and sold. It is engaged in healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). The Company is also engaged in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. It operates in more than 100 countries.
» More Articles for AZN

Headlines

Articles On GuruFocus.com
Last Month Insiders Bought Over $300 Million Of This Biotech Jun 26 2015 
Guru Stocks at 52-Week Lows: XOM, WMT, CVX, AZN, COP Jun 21 2015 
Amgen And AstraZeneca’s Deal On Psoriasis Drug Faces Termination May 27 2015 
Johnson & Johnson A Good Investment Despite Current Lows May 14 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 
Regulus Therapeutics (RGLS) microRNA Therapeutic Milestone Payment, Dave & Buster's Entertainment (P Apr 08 2015 
Pfizer Stocks Has A Lot Of Steam To Take The Investors Higher Jan 20 2015 
Merck Takes A Step Forward In The World Of Medicine Jan 16 2015 
Brandes International Equity Fund Q3 Commentary Dec 23 2014 

More From Other Websites
AstraZeneca and Teva Settle Allegations of Underpaying Medicaid Rebates Jul 06 2015
Questor share tip: AstraZeneca 12-month low is a buying opportunity Jul 04 2015
Former GE CIO, Now an Investor, Offers Advice on Selecting Emerging Tech Jul 02 2015
AstraZeneca rises on drug pipeline hopes Jul 02 2015
3 Of The Best Dividend Stocks That Money Can Buy: AstraZeneca plc, SSE PLC And Premier Farnell plc Jul 02 2015
AstraZeneca upgraded by Berenberg Jul 02 2015
Berenberg ups AstraZeneca to 'buy'; says oncology pipeline will drive growth Jul 02 2015
AstraZeneca updates on immuno-oncology combinations development programme at ASCO 2015 Jul 01 2015
BUZZ-AstraZeneca: FDA move makes Symbicort generics more likely Jul 01 2015
Why I’m Buying More AstraZeneca plc As It Hits A 52-Week Low Jun 30 2015
4 Stocks That Are Trading Far, Far Too Cheaply: AstraZeneca plc, Old Mutual plc, Aberdeen Asset... Jun 26 2015
HSBC initiates coverage of European pharmaceuticals Astra, GSK, Hikma and Shire Jun 26 2015
Boris Johnson to suggest creating a "megafund" for biotech firms Jun 25 2015
Why Vectura Group PLC Could Be The Perfect Partner For AstraZeneca plc In Your Portfolio Jun 25 2015
AstraZeneca loses second top executive as Vectura gets new CEO Jun 24 2015
Vectura Group appoints AstraZeneca executive as CEO Jun 24 2015
Redx Pharma enjoys good progress during first-half Jun 22 2015
Lions Health Announces Winners Jun 21 2015
AstraZeneca appoints Pam Cheng as Executive Vice President, Operations and IT Jun 18 2015
Chi-Med Arthritis Drug Spurs Interest From Potential Partners Jun 18 2015
Is Alliance Pharma plc The Perfect Partner For AstraZeneca plc In Your Portfolio? Jun 18 2015
Should You Buy These High-Yielding Shares? HSBC Holdings plc, AstraZeneca plc & Laura Ashley... Jun 16 2015
AstraZeneca appoints Pam Cheng as Executive Vice President, Operations and IT Jun 16 2015
AstraZeneca Presents Phase III Data on Gout Drug Lesinurad - Analyst Blog Jun 15 2015
AstraZeneca presents new positive phase III data on triple therapy approach with dapagliflozin,... Jun 15 2015
Looking For Pounding Payout Potential? Check Out AstraZeneca plc, Kier Group plc, Marston’s PLC &... Jun 15 2015
AstraZeneca R&D executive Morrison to lead cancer firm Syndax Jun 15 2015
AstraZeneca R&D executive Morrison to lead cancer firm Syndax Jun 15 2015
BUZZ-AstraZeneca Pharma India resumes surge Jun 15 2015
AstraZeneca Announces Phase III Results for Lesinurad in Combination with Febuxostat in Tophaceous... Jun 13 2015
Edited Transcript of FGEN presentation 10-Jun-15 9:00pm GMT Jun 13 2015
Neil Woodford Buys Horizon Discovery Group PLC And More GlaxoSmithKline plc & AstraZeneca plc Jun 12 2015
Cramer: My take on the Twitter showdown Jun 11 2015
New real-world data analysis finds no evidence of increased risk of hospitalisation for heart... Jun 11 2015
Which Is The Best Dividend Stock: AstraZeneca plc, United Utilities Group PLC Or Stagecoach Group... Jun 11 2015
Thursday newspaper round-up: Iraq, UK house prices, Greece Jun 11 2015
Top AstraZeneca R&D Exec Leaves to Run a Private Drugmaker Jun 10 2015
AstraZeneca Research Executive Morrison Is Leaving Company Jun 10 2015
AstraZeneca R&D boss Morrison leaves to head private drugmaker Jun 10 2015
AstraZeneca R&D boss Morrison leaves to head private drugmaker Jun 10 2015
AstraZeneca’s Chief Medical Officer to Depart After Three Years Jun 10 2015
AstraZeneca research head Morrison leaves to head biotech firm Jun 10 2015
AstraZeneca plc: Best To Stay On The Sidelines? Jun 10 2015
Cholesterol Awareness Initiative Makes Its Move Across America Jun 08 2015
New real-world data analysis finds no evidence of increased risk of hospitalisation for heart... Jun 08 2015
AstraZeneca presents new positive phase III data on triple therapy approach with dapagliflozin,... Jun 06 2015
Pfizer CEO: The Story Behind Ian Read Jun 03 2015
Ardelyx Regains Worldwide Development and Commercialization Rights for Its Late-Stage Development... Jun 03 2015
AstraZeneca to present data demonstrating progress of its comprehensive diabetes portfolio at the... Jun 03 2015
AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for... Jun 02 2015
AstraZeneca Quote Puts Juno On Rumor Rollercoaster Jun 02 2015
UPDATE 2-AstraZeneca would consider buying immune-therapy company - Bbg Jun 02 2015
Actavis Affirms Commitment To Advancing Antibiotic Stewardship At White House Forum Jun 02 2015
AstraZeneca in Algeria $125 mn pharmaceuticals deal Jun 02 2015
AstraZeneca updates on immuno-oncology combinations development programme at ASCO 2015 Jun 02 2015
FTSE falls, with oil and gas stocks a drag Jun 01 2015
AstraZeneca and MedImmune present positive immuno-oncology combination data at ASCO 2015 May 30 2015
AstraZeneca and Lilly to collaborate on Immuno-oncology combination clinical trial in solid tumours May 29 2015
Medimmune and Immunocore announce new collaboration to conduct immuno-oncology combination trials in... May 28 2015
Teva pays $1.2 billion to settle pay-for-delay allegations May 28 2015
AstraZeneca announces updated progression free survival data for investigational non-small cell lung... May 27 2015
AstraZeneca hit after psoriasis drug linked to suicide fears May 26 2015
Amgen ends work on experimental psoriasis drug May 22 2015
AstraZeneca provides update on brodalumab development programme May 22 2015
AstraZeneca to invest $285 million in Swedish biotech drug factory May 18 2015
AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden, to support... May 18 2015
AstraZeneca to update on progress with immuno-oncology pipeline and combination treatments at ASCO... May 13 2015
Medicare data show contrast in generic, brand prescribing Apr 30 2015
Medicare figures show generic, brand prescribing Apr 30 2015
AstraZeneca insists Celgene deal about strategy, not cash Apr 24 2015
AstraZeneca profit falls as patent expires on heartburn drug Apr 24 2015
AstraZeneca looks beyond Nexium hit with new cancer deals Apr 24 2015
FTSE rises to record as retailers advance Apr 15 2015
AstraZeneca immune system drug wins orphan status in rare cancer Apr 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK